Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Long-Term Investments (2025)

NewAmsterdam Pharma's Long-Term Investments history spans 1 years, with the latest figure at $92.6 million for Q4 2025.

  • For Q4 2025, Long-Term Investments changed N/A year-over-year to $92.6 million; the TTM value through Dec 2025 reached $92.6 million, changed N/A, while the annual FY2025 figure was $92.6 million, N/A changed from the prior year.
  • Long-Term Investments for Q4 2025 was $92.6 million at NewAmsterdam Pharma, up from $53.1 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $92.6 million in Q4 2025 and bottomed at $44.2 million in Q2 2025.